Anumana is a company that is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Pulse 2.0 interviewed Anumana CEO Maulik Nanavaty to learn more about the company.
Anumana: Interview With CEO Maulik Nanavaty About The AI-Driven Health Technology Company
Related Articles
Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it
Healthcare IT News: Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to…April 13, 2021
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.December 16, 2022
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Philips Launches ECG-AI Marketplace to Enhance Early Cardiac Diagnosis
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystemJuly 17, 2025